RxDoctor Payments Data

Steven Mercado, MD

Internal Medicine · San Antonio, TXNPI 1043615503

Payments from drug & device makers

$13,642in general payments, 2019–2025

Across 367 payments — averaging $37.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$1K
  • Nevro Corp.$872
  • plus $6K from 43 others

What the payments were for

  • Food & beverage$13,642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,642 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,743
Medicare patients
225
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$161,241
JardianceEmpagliflozin128$121,402
EliquisApixaban183$114,186
MounjaroTirzepatide25$42,334
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$34,258
FarxigaDapagliflozin Propanediol25$24,616
XareltoRivaroxaban18$23,366
TrulicityDulaglutide17$21,850
MyrbetriqMirabegron52$21,736
VascepaIcosapent Ethyl35$19,475
Tresiba Flextouch U-200Insulin Degludec15$16,562
EntrestoSacubitril/Valsartan29$10,145
BrilintaTicagrelor31$8,896
Tresiba Flextouch U-100Insulin Degludec11$6,838
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,646$161,241104 claims
Boehringer IngelheimJardiance$227$121,402128 claims
PfizerEliquis$141$114,186183 claims
Lilly USA, LLCMounjaro, Trulicity$1,244$64,18342 claims
GSKTrelegy Ellipta, Anoro Ellipta$657$40,13463 claims
AstraZenecaFarxiga, Brilinta$1,285$33,51256 claims
Johnson & JohnsonXarelto$1,003$23,36618 claims
Astellas Pharma US IncMyrbetriq$150$21,73652 claims
NovartisEntresto$177$10,14529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →